Pharmacotherapeutics of SARS-CoV-2 Infections

Bhavesh D Kevadiya; Jatin Machhi; Jonathan Herskovitz; Maxim D Oleynikov; Wilson R Blomberg; Neha Bajwa; Dhruvkumar Soni; Srijanee Das; Mahmudul Hasan; Milankumar Patel; Ahmed M Senan; Santhi Gorantla; JoEllyn McMillan; Benson Edagwa; Robert Eisenberg; Channabasavaiah B Gurumurthy; St Patrick M Reid; Chamindie Punyadeera; Linda Chang; Howard E Gendelman

doi:10.1007/s11481-020-09968-x

Pharmacotherapeutics of SARS-CoV-2 Infections

J Neuroimmune Pharmacol. 2021 Mar;16(1):12-37. doi: 10.1007/s11481-020-09968-x. Epub 2021 Jan 6.

Authors

Bhavesh D Kevadiya¹, Jatin Machhi², Jonathan Herskovitz^{2

3}, Maxim D Oleynikov², Wilson R Blomberg², Neha Bajwa⁴, Dhruvkumar Soni⁵, Srijanee Das^{2

3}, Mahmudul Hasan⁵, Milankumar Patel², Ahmed M Senan⁶, Santhi Gorantla², JoEllyn McMillan², Benson Edagwa², Robert Eisenberg⁷, Channabasavaiah B Gurumurthy², St Patrick M Reid³, Chamindie Punyadeera⁸, Linda Chang⁹, Howard E Gendelman^{2

3

5}

Affiliations

¹ Department of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, NE, 68198-5880, USA. [email protected].
² Department of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, NE, 68198-5880, USA.
³ Department of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
⁴ Department of Pharmaceutical Sciences & Technology, Maharaja Ranjit Singh Punjab Technical University, Bathinda, Pb, India.
⁵ Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
⁶ Glycomics and Glycan Bioengineering Research Center (GGBRC), College of Food Science and Technology, Nanjing Agricultural University, Nanjing, 20095, China.
⁷ Private Citizen, Omaha, NE, 68198, USA.
⁸ The School of Biomedical Sciences and the Institute of Health and Biomedical Innovation, Queensland University of Technology and the Translational Research Institute, Brisbane, Australia.
⁹ Departments of Diagnostic Radiology & Nuclear Medicine, and Neurology, School of Medicine, University of Maryland, Baltimore, MD, 21201, USA.

Abstract

The COVID-19 pandemic has affected more than 38 million people world-wide by person to person transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Therapeutic and preventative strategies for SARS-CoV-2 remains a significant challenge. Within the past several months, effective treatment options have emerged and now include repurposed antivirals, corticosteroids and virus-specific antibodies. The latter has included convalescence plasma and monoclonal antibodies. Complete viral eradication will be achieved through an effective, safe and preventative vaccine. To now provide a comprehensive summary for each of the pharmacotherapeutics and preventative strategies being offered or soon to be developed for SARS-CoV-2.

Keywords: Antibodies; Antivirals; COVID-19 therapeutics; SARS-CoV-2; Vaccine.

Publication types

Research Support, N.I.H., Extramural
Review

MeSH terms

Antibodies, Viral / therapeutic use
Antiviral Agents / pharmacology
COVID-19 / prevention & control
COVID-19 / transmission
COVID-19 Drug Treatment*
COVID-19 Vaccines
Drug Repositioning
Humans

Substances

Antibodies, Viral
Antiviral Agents
COVID-19 Vaccines

Abstract

Publication types

MeSH terms

Substances

Grants and funding